New York-based SELLAS Life Sciences (Nasdaq: SLS) is on track to complete enrollment for its Phase III REGAL study of galinpepimut-S (GPS).
SELLAS, which is working on the development of novel therapies for a broad range of cancer indications, has in-licensed the candidate from immunotherapy specialist Advaxis (Nasdaq: ADXS).
Galinpepimut-S has demonstrated positive Phase II clinical results in acute myeloid leukemia and malignant pleural mesothelioma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze